The Valencian dermocosmetic research laboratory, specialized in supporting claims of efficacy and functionality through in vitro and ex vivo tests and clinical studies on human volunteers, has closed the first half of 2025 with an increase of 39.8% compared to the same period of the previous year. This growth is in addition to the upward trajectory recorded throughout 2024, a year in which Dermaclaim reached a total turnover of more than €2 million, which represented an increase of 38.9% compared to 2023.
During the first half of 2025, 53% of turnover corresponded to studies on functional ingredients, while 47% corresponded to tests on final cosmetic products or oral nutraceuticals. It is also important to note that 78% of revenues came from international customers, while 22% of turnover corresponded to domestic customers.
In line with its sustainable growth strategy, Dermaclaim is finalising the adaptation of its new own facilities, which will be operational at the beginning of September. These facilities, whose work began in March after more than six months of administrative procedures, will allow the unification of the company’s two departments (laboratory and clinical research) in a single work center. This consolidation will double current capacities, while eliminating dependence on public spaces such as those of the SCSIE-UV, where the laboratory department is currently located, also improving response times and expanding the possibilities of growth at the level of staff and portfolio of services.
” We are at a key moment for Dermaclaim’s growth. With only four years of activity, having reached this volume of business is a clear sign of the team’s effort and the confidence of our customers in our testing services. Our biggest challenge now is to have the new facilities perfectly ready after the summer, to ensure a quick transition that does not affect our customers and allows us to start the new clinical studies, planned from August 25th. We will continue to bet on solid and rigorous growth, aligned with market demand.”– says David González, CEO of Dermaclaim Lab S.L.
In the same way that there will be a significant advance at the level of its own facilities, the company has made considerable investments in equipment to improve the quality of its services and complement the portfolio of studies offered. At the clinical level, new equipment has been acquired, including the Visia-CR (5th Gen.) from Canfield, different probes such as the VapoMeter, MoistureMeter SC, MoistureMeterEpiD, SebumScale or ElastiMeter from Delfin Technologies, the C-Cube with 3D from Pixience, as well as completing the duplication of all the Courage-Khazaka probes to be able to continue offering the service without interruptions, despite possible breakdowns or damage to the current probes.
In the same way, the laboratory department will be equipped with all the necessary equipment to depend solely on external facilities, with regard to the equipment with the highest economic cost, such as the confocal microscope, massive sequencers, or HPLC and chromatography equipments.
Advertorial
CONTACT
Dermaclaim
